CROI 2026: Low levels of bNAbs detected in rectal tissue up to 46 weeks post infusion
12 May 2026. Related: Early access, Conference reports, Cure-related research.
Early access
Liverpool University launches new PrEP drug interaction website: covers oral, injectable and ring-based PrEP
6 May 2026. Related: Early access, PK and drug interactions.
Long-lived macrophages might explain unsuppressible low-level viraemia on ART
6 May 2026. Related: Early access, Treatment strategies, Virology, Drug resistance.
CROI 2026: Nine comprehensive free reviews in Topics in Antiviral Medicine
6 May 2026. Related: Early access, Conference reports.
Transgender health in Australia: HIV drops by 94% as PrEP increases over 10 years
2 May 2026. Related: Journal scan, Early access, HIV prevention and transmission.
BHIVA 2026: HIV and neurodiversity includes higher concerns over adherence
1 May 2026. Related: Early access, Conference reports, Coinfections and complications.
US FDA and Japan approve new once-daily oral HIV combination of doravirine/islatravir (IDVYNSO)
21 April 2026. Related: Early access, Antiretrovirals.
US CDC stops testing services for key infectious diseases: rabies, mpox, measles, EBV, SARS and others
8 April 2026. Related: Early access, Activism & advocacy.
Psilocybin is 6-fold more effective than nicotine patches to stop smoking in pilot US study with CBT
7 April 2026. Related: Journal scan, Early access.
Update on Gilead’s once-weekly oral HIV GS-1720 and GS-4182 studies
2 April 2026. Related: Early access, Antiretrovirals.
Two cases of severe hyperglycemia with injectable CAB/RPV-LA
5 March 2026. Related: Journal scan, Early access, Side effects.